SNMMI 2023

(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24^th and 27^th, 2023 was host to a prostate cancer session. Dr. Angela Castellanos Rieger presented the results of an analysis evaluating the prognostic value of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) among castrate-resistant prostate cancer (CRPC) patients in the pre-chemotherapy, post-androgen receptor signaling inhibitor (ARSI) treatment setting.

(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24^th and 27^th, 2023 was host to a prostate cancer session. Dr. Jinhui Yang presented the results of an analysis evaluating the role of ⁶⁸Ga-PSMA PET/CT-based multivariable modeling for the diagnosis of clinically significant prostate cancer (csPCa) in patients with PSA levels in the 4-10 ng/ml range.

(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24^th and 27^th, 2023 was host to a prostate cancer radiotracers session. Dr. Jens Kurth presented the results of an intra-individual analysis comparing the performance characteristics of [⁶⁸Ga]Ga-RM2 and [⁶⁸Ga]Ga-PSMA PET/CT in metastatic castrate-resistant prostate cancer (mCRPC) patients.

(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24^th and 27^th, 2023 was host to a prostate cancer session. Melanie Hohberg presented the results of an analysis evaluating whether tumor-to-kidney ratio on pre-treatment PSMA-PET/CT was predictive of treatment response in metastatic castrate-resistant prostate cancer (mCRPC) patients.

(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Harshad Kulkarni discussing personalized PSMA-directed molecular radiotherapy with identification of favorable genomic and post-therapeutic radiomic parameters. With the publication of the VISION trial, the FDA and EMA subsequently approved the use of Lu-177 PSMA-617 in the third line setting of metastatic castration-resistant prostate cancer (mCRPC) treatment.¹

(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Isabel Rauscher discussing safety and efficacy of ¹⁷⁷Lu-PSMA-I&T radioligand therapy in octogenarians with metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177 PSMA radioligand therapy is a new treatment option for mCRPC and has received recent FDA approval based on the results of the VISION trial.¹

(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Thomas Huettmann discussing the impact of higher SUV mean in baseline ¹⁸F-PSMA 1007 PET and the association with survival in patients undergoing radioligand therapy with [¹⁷⁷Lu]Lu-PSMA I&T.

(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24^th and 27^th, 2023 was host to a prostate cancer session. Dr. Mahbod Jafarvand presented the results of a single center, retrospective analysis evaluating PSMA-PET/CT for prostate cancer patients following focal therapy.

(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24^th and 27^th, 2023 was host to a prostate cancer session. Dr. Ahmad Abdelrazek presented the results of a real-world, retrospective analysis evaluating the early adverse events, emergency room visits, and hospitalizations following prostate-specific membrane antigen (PSMA)-based radioligand therapy (RLT).

(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24^th and 27^th, 2023 was host to a prostate cancer session. Dr. Kilian Kluge presented the results of an analysis evaluating the effects of anti-hormonal treatment status on ⁶⁸Ga-PSMA-HBED-CC positron emission tomography (PET) biodistribution in prostate cancer patients.

(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24^th and 27^th, 2023 was host to a session on urologic malignancies. Dr. Jeremie Calais presented the results of the ZIRCON phase 3 trial (NCT03849118) that evaluated the test performance characteristics of ⁸⁹Zr-DFO-girentuximab PET/CT imaging for the accurate detection of clear cell renal cell carcinoma (RCC) primary and secondary lesions in patients with renal masses detected via conventional imaging.

(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24^th and 27^th, 2023 was host to a session on urologic malignancies. Following his earlier presentation of the ZIRCON phase 3 study results in the overall cohort, Dr. Calais next presented results from the UCLA cohort of this trial.

(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24^th and 27^th, 2023 was host to a session on urologic malignancies. Dr. Saurav Jha presented the results of an analysis comparing ⁶⁸Ga-PSMA-PET/CT and ¹⁸F-FDG-PET/CT in the metastatic work up of renal cell carcinoma (RCC).

(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24^th and 27^th, 2023 was host to a session on urologic malignancies. Dr. Piyush Aggarwal presented the results of an analysis comparing early response assessment to tyrosine kinase inhibitors (TKIs) in metastatic clear cell renal cell cancer (RCC) using ⁶⁸Ga-PSMA-11-PET versus contrast-enhanced computed tomography (CT).

(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a session on urologic malignancies. Dr. Lena Unterrainer presented the results of an analysis evaluating changes in c-MET expression in metastatic renal cell carcinoma (RCC) patients using c-MET-targeted PET imaging.

(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Phillip Kuo discussing a post-hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies to assess the impact of urinary activity on interpretation of ¹⁸F-rhPSMA-7.3 PET/CT. Radiohybrid (rh) ¹⁸F-rhPSMA-7.3 is a novel high affinity PSMA-targeting PET radiopharmaceutical currently under investigation as a diagnostic imaging tool for patients with prostate cancer:

(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Minseok Suh discussing preliminary results of safety, dosimetry, and efficacy in a phase I/II clinical trial of ¹⁷⁷Lu-DGUL in metastatic castration-resistant prostate cancer (mCRPC) patients.

(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Muheon Shin discussing predictive features of ¹⁸F-DCFPyL PSMA PET/MRI in high-risk prostate cancer patients treated with neoadjuvant chemohormonal therapy prior to radical prostatectomy. Neoadjuvant chemohormonal therapy followed by cytoreductive radical prostatectomy is a novel and emerging therapeutic approach in patients with newly diagnosed high-risk primary prostate cancer with oligometastatic disease.

(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Andrew Nguyen discussing Re-SPECT, a study assessing patient outcomes following a response biomarker guided approach to treatment using ¹⁷⁷Lu-PSMA-I&T in men with metastatic castrate resistant prostate cancer (mCRPC). ¹⁷⁷LuPSMA is an effective treatment in mCRPC with trials, such as VISION and TheraP, adopting a standardized dose interval.^1,2

(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Anushna Babu discussing dual PSMA/FDG PET/CT for assessing eligibility and predicting response in mCRPC patients undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy. Even though baseline PSMA expression is a requisite to successful radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC), there is a subset of patients who do not respond to therapy.